Imaging Markers of Progression in Parkinson's Disease

Antonio P Strafella, Nico I. Bohnen, Nicola Pavese, David E Vaillancourt, Thilo van Eimeren, Marios Politis, Alessandro Tessitore, Christine Ghadery, Simon Lewis
2018 Movement Disorders Clinical Practice  
Parkinson's disease (PD) is the second-most common neurodegenerative disorder after Alzheimer's disease; however, to date, there is no approved treatment that stops or slows down disease progression. Over the past decades, neuroimaging studies, including molecular imaging and MRI are trying to provide insights into the mechanisms underlying PD. This work utilized a literature review. It is now becoming clear that these imaging modalities can provide biomarkers that can objectively detect brain
more » ... hanges related to PD and monitor these changes as the disease progresses, and these biomarkers are required to establish a breakthrough in neuroprotective or disease-modifying therapeutics. Here, we provide a review of recent observations deriving from PET, single-positron emission tomography, and MRI studies exploring PD and other parkinsonian disorders.
doi:10.1002/mdc3.12673 pmid:30637278 pmcid:PMC6277366 fatcat:mseo6ql3xjfh7b56akm6qpdff4